← Back to Search

GLP1 receptor agonist

RGT001-075 for Type 2 Diabetes

Phase 2

Waitlist Available

Research Sponsored by Regor Pharmaceuticals Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 16 weeks

Awards & highlights

Study Summary

This trial is testing a new diabetes drug to see if it's better than placebo. It's for people with type 2 diabetes who are already taking metformin.

Eligible Conditions

Type 2 Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 16 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 16 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in HbA1c from baseline to end of treatment in the modified intent-to-treat population

Secondary outcome measures

Change in body mass index from baseline to end of treatment in the modified intent-to-treat population

Change in fasting plasma glucose from baseline to end of treatment in the modified intent-to-treat population

Change in mean blood lipids including triglycerides (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) from baseline to end of treatment in the modified intent-to-treat population

+34 more

Trial Design

7Treatment groups

Experimental Treatment

Placebo Group

Group I: Dose Group FExperimental Treatment1 Intervention

Group II: Dose Group EExperimental Treatment1 Intervention

Group III: Dose Group DExperimental Treatment1 Intervention

Group IV: Dose Group CExperimental Treatment1 Intervention

Group V: Dose Group BExperimental Treatment1 Intervention

Group VI: Dose Group AExperimental Treatment1 Intervention

Group VII: Placebo GroupPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Regor Pharmaceuticals Inc.Lead Sponsor

4 Previous Clinical Trials

174 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this investigation accepting new participants?

"Clinicaltrials.gov does not show this clinical trial actively recruiting patients; the protocol was initially posted on March 29th 2022 and saw its most recent edit occur on May 17th of the same year. Despite this, there are still 1439 experiments that are ardently searching for volunteers at present time."

Answered by AI

Is participation in this clinical study limited to adults or can minors also engage?

"According to the enrollment criteria for this trial, the lowest possible age of consent is 18 while the uppermost limit on age is 75."

Answered by AI

Is RGT001-075 a safe option for patients to utilize?

"Drawing from available evidence, the hazard rating of RGT001-075 is scored as a 2 on our risk assessment scale. This is because the drug has been through Phase 2 trials but there are no reports that can vouch for its efficacy yet."

Answered by AI

Does my profile meet the requirements for this clinical experiment?

"This medical study is seeking applicants aged 18-75 years with type 2 diabetes mellitus. The ideal candidate will have a Screening HbA1c of 7.0-10.5%, BMI 24.5 - 40 kg/m2, and be taking metformin ≥1000 mg/day (or maximum tolerated dose) for at least 3 months prior to screening; they must also practice contraception if applicable, not be pregnant or lactating, and agree to comply with the trial's requirements throughout its duration."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

2022. "A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05297045.